McKesson Corporation (MCK)

Over the past six months, McKesson Corp. stock has shown strong performance, with shares soaring 38% over the past 52 weeks. In November 2025, MCK shares hit an all-time high, and the company delivered impressive Q2 fiscal year 2026 results, exceeding analyst expectations, which prompted a surge in its shares. In December 2025, McKesson shares decreased to a 4-week low. In January 2026, McKesson shares increased to a 4-week high, and analysts have maintained a positive rating for MCK, with several firms raising their price targets. McKesson is expected to announce its fiscal Q3 2026 earnings on February 4, 2026.

McKesson Corporation actively addresses demand seasonality for its products and services through advanced analytics and machine learning. The company utilizes expanded data sets and proprietary inventory optimization methods to detect patient dispense demand patterns, seasonality, and volatility. Their predictive machine learning capabilities enable swift inventory purchases ahead of disruptions to fulfill customer demand during forecasted periods of fluctuation.

McKesson Corporation is an American publicly traded healthcare services and information technology company operating in the healthcare sector, specifically within the wholesale and healthcare services industry. Its core business revolves around the distribution of pharmaceuticals and medical supplies, alongside providing health information technology and health management tools, delivering a significant portion of pharmaceutical products consumed in North America. McKesson's major products and services are categorized into four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment focuses on the distribution and logistics of various pharmaceutical drugs and offers solutions to oncology and specialty practices. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and equipment and offers logistics services. The Prescription Technology Solutions (RxTS) segment combines technologies to connect pharmacies, providers, payers, and biopharma for patient access and adherence solutions.

McKesson Corporation is headquartered in Irving, Texas, U.S., with a significant presence across North America and Europe. Its operations span the United States, Canada, and Norway. McKesson Canada's head office is in Montréal, Quebec. The company manages numerous distribution centers, pharmacy locations, and business offices throughout the U.S. and internationally. McKesson has been exiting most of its European wholesale businesses, with one country still under evaluation for exit as of March 2024.

McKesson's brand reputation in the past year has been shaped by its role in healthcare supply chains and its recognition in business rankings, alongside ongoing legal challenges. McKesson played a central role as the U.S. government's centralized distributor for COVID-19 vaccine doses. The company has been named in federal lawsuits for its role in the opioid epidemic in the United States. In 2026, Forbes recognized McKesson on several lists, including "#152 America's Best Companies," indicating a strong standing in terms of company performance, trustworthiness, and employer reputation.

Institutional investors hold a significant portion of McKesson Corp. stock, owning approximately 78% to 88.20% of the shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp., among others. Individual investors and retail ownership account for the remaining portion, with insiders holding a very small percentage.